How do pathogenic bacteria manipulate host cells and cause disease? What molecular structures allow them to accomplish such feats? Here, at the Centre for Blood Research, Dr Natalie Strynadka’s laboratory and colleagues have used cryo-electron microscopy (cryo-EM) to visualize molecular details of the “nano-syringe” Salmonella uses to inject virulence proteins into eukaryotic host cells and cause disease. Their findings have…
Read More
Terry Thomas is a creative, critical thinker who has dedicated her career to inventing technologies for the advancement of stem cell, regenerative medicine and cancer research. As the first scientist hired at STEMCELL Technologies Inc. in 1994, Terry has been seminal in building Canada’s largest biotech company. She has been granted patents for 14 unique technologies personally and 22 more…
Read More
Today Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a specialty pharmaceutical company with expertise in drug delivery and clinical development, and the Centre For Drug Research and Development (“CDRD”), Canada’s national drug development and commercialization centre, announced a broad research collaboration to establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics targeting neurological movement disorders including epilepsy, Multiple Sclerosis,…
Read More
Simon Fraser University researchers are investigating why some older Canadians living with multiple chronic health conditions maintain their resiliency. Professor Andrew Wister, director of SFU’s Gerontology Research Centre, is SFU’s principal investigator for the multi-university Canadian Longitudinal Study on Aging (CLSA). He leads one of 25 research teams benefiting from a share of $1.7 million in CLSA catalyst grants, funded…
Read More
This work focused on developing a new drug that targeted metastatic tumor nodules exhibiting a multidrug resistant (MDR) phenotype. The results showed that this new compound displayed a half-life of 12 h and selectively targeted the tumor nodules compared to the adjacent normal tissue, significantly prolonging the survival of mice bearing metastatic MDR tumors in mice models of advanced breast and ovarian cancers.
Read More
Orkla Food Ingredients has inked a deal with Canada’s Renaissance BioScience to exclusively produce and sell its patent-pending, acrylamide-reducing yeast Acrylow in Nordic and Baltic countries. The ingredient will be rolled out in the third quarter of 2017. Acrylow allows manufacturers to achieve acrylamide reductions of between 50 and 95% depending on the dosage, process, and application.
Read More

REVIEW: Modeling the Process of Human Tumorigenesis

Modelling the genesis of human cancers is at a scientific turning point. Starting from primary sources of normal human cells, it is now possible to reproducibly generate several types of malignant cell populations. Powerful methods for clonally tracking and manipulating their appearance and progression in serially transplanted immunodeficient mice are also in place. These developments circumvent historic drawbacks inherent in…
Read More
To mark Canada’s 150th birthday, we are counting down to Canada Day with profiles of 150 noteworthy British Columbians. In 1971, Dr. Victor Ling was frustrated and full of doubt. It was an unusual period for Ling, who is known for his optimism about finding a cure for cancer. After getting his doctorate at the University of B.C., Ling was at Cambridge…
Read More
It has been known for years, mostly from anecdotal reports and a few trials, that ECT not only improves the symptoms of depression, but also has a positive effect on the symptoms of Parkinson’s disease, often on a different timeline than it antidepressant effects. Yet, despite years of research, understanding of the effect of ECT remain elusive. In recent years, my lab has conducted PET studies trying to understand its mechanism of action and maybe determine why a small percentage…
Read More
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the body’s innate immune system, announces the peer-reviewed publication of proof of principle data in chronic obstructive pulmonary disease (COPD) in the journal, Respiratory Research. The study demonstrates success with Qu Biologics’ QBKPN SSI in reducing airway inflammation in a smoke-induced lung inflammation mouse model of…
Read More